Clinical Trial Goal
To find out:
- The highest dose of LP-168 that’s safe to give
- If LP-168 is safe and works well to treat B-cell leukemia and lymphoma that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have a B-cell disease that has relapsed or is refractory. Some examples include:
- Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymhpoma
- Haircy cell leukemia (HCL)
- Mantle cell lymphoma (MCL)
- Marginal zone lymhpoma (MZL)
- Waldenstrom Macroglobulinemia
- Have not had a blood or marrow transplant (BMT) in the last 3 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
LP-168 is a small molecule inhibitor.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- LP-168 – A pill that you take by mouth 1 or 2 times each day. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved LP-168.
Contacts
Anna Chen, MD, PhD, (206) 335-3820, yu@newavepharma.com
Stephen Anthony, DO, s.anthony@newavepharma.com
Locations
Duke UniverisityRECRUITING
Durham, North Carolina
Ohio State UniversityRECRUITING
Columbus, Ohio
University of CincinnatiRECRUITING
Cincinnati, Ohio
Huntsman Cancer Institute, University of UtahRECRUITING
Salt Lake City, Utah
Sponsors
lead: Newave Pharmaceutical Inc
